Healthcare / Medical DevicesWarsaw
$0.54
-0.00 (-0.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-5.0M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
8.3%
↑Gross Margin
95.8%
↑Debt/Equity
-0.65
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-40.7%
FCF CAGR
—
FCF margin
-1025.1%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $334000.0 · net income $-2.8M · FCF $-3.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $334000.00 | $334000.00 | $990000.00 | $173000.00 | $1.6M |
| Net Income | $-2.8M | $-2.8M | $-8.2M | $-55.2M | $-17.3M |
| EBITDA | $-1.8M | $-1.8M | $-8.4M | $-42.7M | $-15.4M |
| EPS | -0.33 | -0.33 | -0.92 | -4.19 | -1.32 |
| Gross Margin | 95.8% | 95.8% | 99.3% | -28.9% | 41.5% |
| Operating Margin | -624.0% | -624.0% | -477.7% | -4565.9% | -867.0% |
| Net Margin | -834.7% | -834.7% | -829.1% | -31927.7% | -1080.9% |
| Balance Sheet | |||||
| Debt/Equity | -0.65 | -0.65 | -0.61 | -0.68 | 126.23 |
| Current Ratio | 0.03 | 0.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.4M | $-3.4M | $-5.0M | $-7.7M | $-5.8M |
| Returns | |||||
| ROE | 8.3% | 8.3% | 16.7% | 103.4% | -7194.2% |
| Valuation | |||||
| P/B | — | — | — | — | 143.22 |
| Growth & Yield | |||||
| Revenue Growth | -66.3% | -66.3% | 472.3% | -89.2% | — |
| EPS Growth | 64.1% | 64.1% | 78.1% | -218.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.92 → -0.33
Residual
-47.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.